THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Foo
Source: www.prnewswire.com
Amgen Inc. received approval from the US Food and Drug Administration for its drug Evenity, which is used for the treatment of osteoporosis in postmenopausal women who are at high risk of bone fractures. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. The FDA based its approval of EVENITY on the results of two Phase 3 studies.
